Gestational angiogenic biomarker patterns in high risk preeclampsia groups

American Journal of Obstetrics and Gynecology

Volumn 209, Issue 1, 2013, Pages 53.e1-53.e9

  Maynard, Sharon E ^a,b   Crawford, Sybil L ^c   Bathgate, Susanne ^a   Yan, Jing ^d   Robidoux, Laura ^f,h   Moore, Melissa ^a   Moore Simas, Tiffany A ^d,e,f,g,h  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b LEHIGH VALLEY HOSPITAL   (United States)

^c Division of Preventive and Behavioral Medicine   (United States)

^d Departments of Biochemistry and Molecular Pharmacology   (United States)

^e UNIVERSITY OF MASSACHUSETTS   (United States)

^f Departments of Obstetrics and Gynecology   (United States)

^g Departments of Pediatrics   (United States)

^h University of Massachusetts   (United States)

Author keywords

Angiogenic factors; PlGF; Preeclampsia; SEng; SFlt1

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; ENDOGLIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HIGH RISK PREGNANCY; HUMAN; HUMAN TISSUE; HYPERTENSION; MAJOR CLINICAL STUDY; MULTIPLE PREGNANCY; NULLIPARA; OBESITY; OBSERVATIONAL STUDY; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

EID: 84880132971     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2013.03.017     Document Type: Article

References (30)

1. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): Randomised placebo-controlled trial. Lancet 2006;367:1145-54.
2. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-58. (Pubitemid 36278583)
3. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12: 642-9. (Pubitemid 43865232)
4. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350: 672-83. (Pubitemid 38364626)
5. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:992-1005. (Pubitemid 44343543)
6. Verlohren S, Stepan H, Dechend R. Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin Sci (Lond);122: 43-52.
7. American Congress of Obstetricians and Gynecologists. ACOG practice bulletin no. 101. Ultrasonography in pregnancy. Obstet Gynecol 2009;113:451-61.
8. American Congress of Obstetricians and Gynecologists. ACOG practice bulletin no. 33, January 2002. Diagnosis and management of preeclampsia and eclampsia. Int J Gynaecol Obstet 2002;77:67-75.
9. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1-22.
10. Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. New York: Wiley; 2004.
11. Maynard SE, Moore Simas TA, Solitro MJ, et al. Circulating angiogenic factors in singleton vs multiple-gestation pregnancies. Am J Obstet Gynecol 2008;198:200.e1-7.
12. Powers RW, Jeyabalan A, Clifton RG, et al. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One 2010;5:e13263.
13. Sanchez O, Llurba E, Marsal G, et al. First trimester serum angiogenic/anti-angiogenic status in twin pregnancies: Relationship with assisted reproduction technology. Hum Reprod 2012;27:358-65.
14. Bdolah Y, Lam C, Rajakumar A, et al. Twin pregnancy and the risk of preeclampsia: Bigger placenta or relative ischemia? Am J Obstet Gynecol 2008;198:428.e1-6.
15. Dwyer BK, Krieg S, Balise R, et al. Variable expression of soluble fms-like tyrosine kinase 1 in patients at high risk for preeclampsia. J Mater-Fetal Neonatal Med 2010; 23:705-11.
16. Rajakumar A, Michael HM, Rajakumar PA, et al. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005;26:563-73. (Pubitemid 40916309)
17. Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclampsia patients. Am J Obstet Gynecol 2012;206:58.e1-8.
18. O'Brien TE, Ray JG, Chan WS. Maternal body mass index and the risk of preeclampsia: A systematic overview. Epidemiology 2003;14: 368-74. (Pubitemid 40417091)
19. Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) Study. Associations with maternal body mass index. BJOG;117:575-84.
20. Bodnar LM, Ness RB, Harger GF, Roberts JM. Inflammation and triglycerides partially mediate the effect of prepregnancy body mass index on the risk of preeclampsia. Am J Epidemiol 2005;162:1198-206. (Pubitemid 41785914)
21. Hauth JC, Clifton RG, Roberts JM, et al. Maternal insulin resistance and preeclampsia. Am J Obstet Gynecol 2011;204:327.e1-6.
22. Herse F, Fain JN, Janke J, et al. Adipose tissue-derived soluble fms-like tyrosine kinase 1 is an obesity-relevant endogenous paracrine adipokine. Hypertension 2011;58: 37-42.
23. Kaess BM, Pedley A, Massaro JM, et al. Relation of vascular growth factors with CTderived measures of body fat distribution: The Framingham Heart Study. J Clin Endocrinol Metab 2012;97:987-94.
24. Lynch AM, Murphy JR, Gibbs RS, et al. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with preeclampsia. BJOG 2010;117:456-62.
25. Mijal RS, Holzman CB, Rana S, Karumanchi SA, Wang J, Sikorskii A. Midpregnancy levels of angiogenic markers in relation to maternal characteristics. Am J Obstet Gynecol 2011;204:244.e1-12.
26. Straughen JK, Misra DP, Kumar P, Misra VK. The influence of overweight and obesity on maternal soluble fms-like tyrosine kinase 1 and its relationship with leptin during pregnancy. Reprod Sci 2013;20:269-75.
27. Suwaki N, Masuyama H, Nakatsukasa H, et al. Hypoadiponectinemia and circulating angiogenic factors in overweight patients complicated with pre-eclampsia. Am J Obstet Gynecol 2006;195:1687-92. (Pubitemid 44792620)
28. Wolf M, Shah A, Lam C, et al. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol 2005;193:16-22. (Pubitemid 40991821)
29. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: Systematic review of controlled studies.BMJ2005;330:565.
30. Eastabrook G, Brown M, Sargent I. The origins and end-organ consequence of preeclampsia. Best Pract Res Clin Obstet Gynecol 2011;25:435-47.